SEMAGLUTIDE TABLET

  • new oral diabetes obesity drug s india sales surge 100

    New oral diabetes + obesity drug's India sales surge 100%

    ​The anti-obesity market has itself tripled because of Rybelsus," said Sheetal Sapale, vice president, commercial at Pharmarack. From ₹24 crore in April 2022, sales of the drug have soared to ₹147 crore in April 2023, and further to ₹363 crore in April this year.

Join the community of 2M+ industry professionals

Subscribe to our Daily Newsletter

By continuing you agree to our Privacy Policy & Terms & Conditions

Download ETHealthworld App for Realtime updates

Seamless reading experience. Save your favourite.

Scan to download App

Download ETHealthworld App for Realtime updates of content you follow

  • Seamless reading experience
  • Save your favourite articles
Advertisement
Advertisement